Understanding NK Cell Function in Prostate Cancer Across Races

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study that collects blood and, when available, tissue samples from men with primary prostate cancer treated at the University of Minnesota. Researchers will examine immune cell markers, especially NK cells, using a 42-marker panel, and review clinical data on disease and outcomes. The project also develops pre-clinical tests of a new trispecific engager targeting B7-H3/PSMA, using de-identified donor samples. Residual tissue may be used for multiplex immunofluorescence and spatial analysis. All activities are non-interventional and rely on consent and existing clinical material.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* AIM 1:

  * Diagnosis (or presumed diagnosis) of primary Prostate cancer
  * 18 years of age or older
  * Has a planned visit to a University of Minnesota Cancer Clinic
  * Willing and able to sign voluntary written consent

Exclusion Criteria:

* AIM 1:

  * Inability or unwillingness to give written informed consent

Where it's running

• University of Minnesota/Masonic Cancer Center
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Nicholas A Zorko — Masonic Cancer Center, University of Minnesota

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRI or CT planning to guide high-dose-rate prostate brachytherapy

  This trial tests whether adding an MRI to CT-based treatment planning for HDR prostate brachytherapy changes urinary side effects in men with localized prostate cancer.

  Recruiting at 3 sites Emory University · Atlanta, Georgia and 2 other locations · NCT07859722

• Targeted Early Detection for Men at High Genetic Risk for Prostate Cancer

  This study tests urinary biomarkers and PSA to see if they can improve early detection for men with a strong family or genetic risk for prostate cancer.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07645391

• Urine and MRI approach to find aggressive prostate cancer early

  This study tests whether a urine test called MPS2, paired with MRI, can better detect aggressive prostate cancer in men 50–75 at risk, possibly reducing unnecessary biopsies.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07526545

• GET FIT Together: a socially enhanced exercise program for older men with prostate cancer

  This program tests whether adding structured social support to supervised online exercise reduces cancer-related loneliness and improves mental and physical health in men 65 and older who have had prostate cancer.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT07504835

• Improved MRI methods to distinguish benign from cancerous pelvic findings

  This test tries new deep-learning image-processing methods on MRI scans to get clearer images faster for adults scanned for prostate screening or suspected endometriosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07407959

• Decision support to help germline genetic testing for men with prostate cancer

  A tool is being tested to help men with prostate cancer decide about germline genetic testing and see if it increases testing completion.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07377006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.